Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
Adolescent
Antitubercular Agents
/ adverse effects
Area Under Curve
Chemical and Drug Induced Liver Injury
/ epidemiology
Child
Child, Preschool
Female
Humans
Indonesia
Infant
Infant, Newborn
Isoniazid
/ blood
Male
Prospective Studies
Pyrazinamide
/ blood
Rifampin
/ blood
Tuberculosis, Meningeal
/ drug therapy
microbiology
pharmacology
therapeutics
Journal
Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
14
12
2020
accepted:
14
06
2021
pubmed:
30
6
2021
medline:
14
1
2022
entrez:
29
6
2021
Statut:
ppublish
Résumé
To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM). Prospective observational pharmacokinetic study with an exploratory pharmacokinetic/pharmacodynamic analysis. Hasan Sadikin Hospital, Bandung, Indonesia. Individuals aged 0-18 years clinically diagnosed with TBM and receiving first-line anti-tuberculosis drug dosages according to revised WHO-recommended treatment guidelines. Plasma and cerebrospinal fluid (CSF) concentrations of isoniazid, rifampicin and pyrazinamide were assessed on days 2 and 10 of treatment. Plasma exposures during the daily dosing interval (AUC Among 20 eligible patients, geometric mean AUC Higher rifampicin doses are strongly warranted in treatment of children and adolescents with TBM. The association between higher plasma concentrations of isoniazid, rifampicin and pyrazinamide and the development of DILI needs confirmatory studies.
Identifiants
pubmed: 34183327
pii: archdischild-2020-321426
doi: 10.1136/archdischild-2020-321426
pmc: PMC8685623
doi:
Substances chimiques
Antitubercular Agents
0
Pyrazinamide
2KNI5N06TI
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
70-77Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Tuberc Lung Dis. 2004 Apr;8(4):500-3
pubmed: 15141745
Clin Infect Dis. 2016 Nov 1;63(suppl 3):S63-S74
pubmed: 27742636
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9
pubmed: 26810651
Diagn Microbiol Infect Dis. 2014 Aug;79(4):441-7
pubmed: 24985764
Clin Infect Dis. 2020 Apr 10;70(8):1774-1780
pubmed: 31560376
Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7
pubmed: 21968358
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30224533
BMC Infect Dis. 2016 Apr 02;16:144
pubmed: 27039088
Lancet Respir Med. 2018 Sep;6(9):662-664
pubmed: 30191832
Eur Respir J. 2019 Dec 12;54(6):
pubmed: 31515410
Int J Antimicrob Agents. 2016 Oct;48(4):415-21
pubmed: 27526979
Lancet Neurol. 2005 Mar;4(3):160-70
pubmed: 15721826
Int J Tuberc Lung Dis. 2014 Feb;18(2):188-95, i-iii
pubmed: 24429311
Eur Respir J. 2016 Jun;47(6):1867-9
pubmed: 26989104
Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52
pubmed: 17021358
Pediatr Infect Dis J. 2014 Mar;33(3):248-52
pubmed: 24168978
Int J Antimicrob Agents. 2019 Sep;54(3):371-374
pubmed: 31202922
Pediatr Infect Dis J. 2019 Jan;38(1):50-53
pubmed: 30234790
Paediatr Respir Rev. 2020 Nov;36:33-43
pubmed: 32241748
Lancet Infect Dis. 2017 Jan;17(1):39-49
pubmed: 28100438
Arch Dis Child. 2018 Dec;103(12):1150-1154
pubmed: 29514812
Clin Infect Dis. 2012 May;54(10):1388-96
pubmed: 22474220
Clin Infect Dis. 2021 Nov 2;73(9):e3520-e3528
pubmed: 33070176
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29914960
Nat Rev Neurol. 2017 Oct;13(10):581-598
pubmed: 28884751
Clin Infect Dis. 2017 Feb 15;64(4):501-509
pubmed: 28172588
Am J Dis Child. 1987 Jul;141(7):741-3
pubmed: 2884866
Lancet Infect Dis. 2010 Nov;10(11):803-12
pubmed: 20822958
Tuberculosis (Edinb). 2010 Sep;90(5):279-92
pubmed: 20709598
Clin Pharmacokinet. 2012 Aug 1;51(8):481-99
pubmed: 22668340
Trans R Soc Trop Med Hyg. 2017 Nov 1;111(11):520-526
pubmed: 29438557
Clin Infect Dis. 2020 Nov 5;71(8):1817-1823
pubmed: 31665299
Pediatr Rep. 2011 Jun 16;3(2):e16
pubmed: 21772953
Trop Med Int Health. 2009 Nov;14(11):1329-37
pubmed: 19735381
Lancet Infect Dis. 2014 Oct;14(10):947-57
pubmed: 25108337
Lancet Infect Dis. 2013 Jan;13(1):27-35
pubmed: 23103177
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:271-291
pubmed: 28715978
Adv Drug Deliv Rev. 2014 Nov 20;77:3-11
pubmed: 25038549